1. Introduction {#s0005}
===============

It is reported that most of the complex living organisms respond coordinately to different extracellular stimuli in order to maintain normal biological functions, such as endo and exocrine secretion, neurotransmission, smooth muscle contraction, inflammatory responses, modulation of cardiac functions and pain, by activating specific signaling cascades and intracellular programs, such as mitogen activated protein kinases (MAPKs). By engaging and activating MAPKs, cells can regulate and control embryogenesis, cell proliferation, differentiation and death, gene expression, metabolism and survival ([@b0020], [@b0085], [@b0145]). One of the main extracellular signals transducer is receptor tyrosine kinases (RTKs), which upon activation lead to intracellular activation of different signaling pathways that control cell metabolism, growth and apoptosis. Findings from several reports revealed that overexpression or mutation of the RTKs is associated with the development of different types of cancer ([@b0015], [@b0055], [@b0125], [@b0150], [@b0155]). These findings fostered the field of cancer research to develop new and effective anti-cancer agents that target the activation of RTKs. Ultimately, receptor tyrosine kinases inhibitors (RTKIs) were developed to block and diminish the activation of RTKs. Currently, drugs of this class are widely used to treat different types of cancer ([@b0060], [@b0110]).

Gefitinib (GEF) is a small molecule that selectively, reversibly and competitively inhibits RTKs activation, specifically epidermal growth factor receptor (EGFR) activation, resulting in inhibition of tumor growth, proliferation and differentiation and eventually induction of apoptosis in cancerous cells ([@b0015], [@b0055], [@b0160]). Therefore, it is effective in treating NSCLC (non-small cell lung cancer). Since RTKIs inhibit the activation of RTKs in both normal and cancerous cells, RTKIs treatment can result in many but serious side effects ([@b0070], [@b0080], [@b0160], [@b0195]). It has been reported that GEF treatment was associated with recurrent myocardial infarction in patient with metastatic carcinoid tumor ([@b0095]). In that study, Lynch and colleagues reported that GEF treatment induced cardiomyopathy in 56-year-old patient with EGFR-mutated NSCLC. Furthermore, Korashy and his colleagues reported that in-vitro and in-vivo treatment with GEF resulted in significant increase in the apoptotic genes, oxidative stress markers, cardiac enzymes (LDH and CK-MB), hypertrophic genes and formation of reactive oxygen species (ROS) ([@b0075]). Although GEF treatment is associated with the development of cardiac toxicity, the exact mechanism is to be further investigated due to the limited information available about the mechanism of cardiotoxicity induced by GEF.

Recent studies demonstrated that liraglutide (LIRA) treatment was associated with lower risk of cardiovascular diseases and death among patients with type 2 diabetes ([@b0100]). Moreover, LIRA treatment led to an improvement in the cardiac function in response to myocardial infarction in mice ([@b0115]). LIRA is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist that is used to effectively treat patients with type 2 diabetes mellitus either as monotherapy or as combination with other antidiabetic medications ([@b0030], [@b0045], [@b0050]). Despite the documented hypoglycemic effect of LIRA, different studies confirmed that LIRA has an anti-inflammatory and antioxidant effects ([@b0010], [@b0200]). Nevertheless, whether LIRA offers protection against GEF-induced cardiotoxicity is still unclear. Therefore, the main aim of the current study is to investigate the mechanism of toxicity induced by GEF and if LIRA pretreatment can mitigate GEF-induced cardiotoxicity *in-vivo*.

2. Materials and methods {#s0010}
========================

2.1. Animals {#s0015}
------------

The breeding and experimental protocols described in this study were approved by the local institutional research ethics committee (REC) of King Saud University, Riyadh, Saudi Arabia (approval \# KSU-SE-18-40). Animals were obtained from the animal care center at college of Pharmacy, King Saud University, Riyadh, Saudi Arabia and housed in a controlled condition (23 °C and 12 h. light/dark cycle) with free access to standard chow diet and water.

2.2. Experimental design and drug treatment {#s0020}
-------------------------------------------

Male Wistar albino rats (weighing 180--200 g) were used in our study and were randomly divided into 4 groups (10 rats per group). Control group received i.p. injection of normal saline for 28 consecutive days. Rats in LIRA group received i.p. injection of LIRA (Novo Nordisk, Denmark) dissolved in normal saline at a dose of 200 µg/kg once daily for 28 days ([@b0105], [@b0115], [@b0190]). GEF group, however, treated with normal saline for 7 days then with 30 mg/kg GEF (Ark Pharm, USA) by oral gavage for 21 days ([@b0075], [@b0140]). In LIRA + GEF group, rats were pretreated with 200 µg/kg of LIRA (i.p.) once daily for 7 days and then were co-treated with 30 mg/kg GEF orally and LIRA at dose of 200 µg/kg (once daily, (i.p.) for 21 days. Body weight was measured daily throughout the study. The dose of GEF was selected based on previous published article ([@b0075]).

On day 29, rats were anesthetized by intraperitoneal injection of ketamine/xylazine mixture then the blood was collected immediately from the heart and the serum was separated for measuring cardiac enzymes. Consequently, heart tissues were excised and washed twice with ice-cold phosphate buffer saline (PBS) and weighed. After that, heart tissues were fixed in formaldehyde solution (4%) for histopathology studies, while other tissues (n = 5) were homogenized for gene and protein expression studies and biochemical studies. Ratio of heart weight to body weight (HW/BW) was used as an indicator of myocardial mass as described previously ([@b0065], [@b0170]).

2.3. Heart histopathology {#s0025}
-------------------------

Heart tissues from all groups were collected at the time of euthanasia and were fixed immediately in 4% formaldehyde solution. The fixed tissues were then embedded in paraffin and thin sections of 3 µm were prepared using a microtome. Then, paraffin-embedded heart sections were deparaffinized and stained with hematoxylin and eosin (H&E). The severity of cardiac damage was evaluated blindly under an optical microscope by comparing the morphology of the cardiac cells and the nucleus of myocardial fiber cells ([@b0130]) (Olympus BX microscope and DP72 camera).

2.4. Measurement of serum enzymes {#s0030}
---------------------------------

Serum was separated from the whole blood by centrifugation of the coagulated blood at 2000*g* for 10 min at 4 °C. To measure the serum levels of different enzymes, Enzyme-Linked Immunosorbent Assay (ELISA) was used, where kits for Creatine Kinase MB Isoenzyme (CK-MB), cardiac troponin I (cTnI) and N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) were used. Kits were purchased from G-Bioscience (MO, USA) and procedures were conducted according to the manufacturer's protocol.

2.5. Real-time quantitative polymerase chain reaction (RT-qPCR) analysis {#s0035}
------------------------------------------------------------------------

Total cellular RNA was isolated from the heart tissues using RNeasy mini kit (Qiagen, USA) as per manufacturer's protocol. The quality and quantity of the isolated RNA were assessed using NanoDrop™ 8000 Spectrophotometer (ThermoFisher Scientific, USA). Then, the isolated RNA was reverse transcribed to cDNA using TaqMan™ Reverse Transcription kit (ThermoFisher Scientific, USA). Changes in the expression of different genes were quantified by QuantStudio 6 Flex rea-time PCR System (ThermoFisher Scientific, USA) using SYBR green master mix (Bimake, USA) and data was normalized to β-actin, which is used as an internal control. The final concentration of the forward and reverse primers that used was 1 µM. The data acquisition was made during the extension step. Sequences of primers used in this study are listed in [Table 1](#t0005){ref-type="table"}. All primers were purchased from Integrated DNA Technologies (IDT, Belgium). The relative levels of mRNA expression were calculated using ΔΔCt method.Table 1List of primer sequences used in this study.GeneAccession umberPrimer sequences (5′→ 3′)Product length (bp)ReferenceSODNM_017050.1Forward: TTCGTTTCCTGCGGCGGCTT\
Reverse: TTCAGCACGCACACGGCCTT112Designed for this studyNF-κBNM_199267.2Forward: CATGCGTTTCCGTTACAAGTGCGA Reverse: TGGGTGCGTCTTAGTGGTATCTGT85Designed for this studyβ -ActinNM_031144.3Forward: CCAGATCATGTTTGAGACCTTCAA Reverse: GTGGTACGACCAGAGGCATACA87Designed for this study

2.6. Western blot analysis {#s0040}
--------------------------

Proteins were extracted from the heart tissues through homogenization in ice-cold RIPA lysis buffer (ThermoFisher Scientific, USA) that supplemented with cocktail protease inhibitor (ThermoFisher Scientific, USA). Then, the protein lysates were denatured in sample buffer (2x Laemmli buffer, Bio-Rad, USA) and heated at 95 °C for 5 min and the protein concentrations were determined by bicinchoninic acid assay (BCA) method using commercially available kit (Boster Biological Technology, USA). After that, equal amount of proteins (20--50 µg) were resolved in 10% SDS-PAGE gel, then transferred to PVDF membrane (Bio-Rad, USA) and blocked with 5% non-fat dry milk in 0.1% TBST buffer for 2 h. After blocking, membranes were incubated with rabbit anti-nuclear factor kappa B (NF-κB) polyclonal antibody, rabbit anti-superoxide dismutase (SOD) polyclonal antibody (ABclonal Technology, USA), rabbit anti-phospho-ERK1/2 monoclonal antibodies, rabbit anti-phospho-P38 monoclonal antibody, rabbit anti-phospho-SAPK/JNK monoclonal antibody, rabbit anti-phospho-Akt monoclonal antibody, rabbit anti-ERK1/2 monoclonal antibodies, rabbit anti-P38 monoclonal antibody, rabbit anti-SAPK/JNK antibody, rabbit anti-Akt monoclonal antibody and rabbit anti-cleaved poly ADP ribose polymerase (PARP) monoclonal antibody (cell signaling technology, USA) overnight at 4 °C. Then, blots were incubated with the appropriate HRP conjugated secondary antibody (ABclonal Technology, USA) for 1 h. Thereafter, membranes were visualized using chemiluminescence reagent (Merck Millipore, USA) and imaged using a Bio-Rad gel-imaging system (Bio-Rad, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) monoclonal antibody (ABclonal Technology, USA) was used as a housekeeping protein. All the primary antibodies were used in dilution of 1:1000.

2.7. Measurement of superoxide dismutase (SOD) enzyme activity {#s0045}
--------------------------------------------------------------

Frozen heart tissues were homogenized in ice-cold lysis buffer (0.1 mM EDTA, 0.5% Triton X-100 and 50 mM potassium phosphate) and centrifuged at 12,000*g* for 5 min at 4 °C. Then, SOD enzyme activity was measured using EnzyChrom^TM^ Superoxide Dismutase Assay Kit (BioAssay Systems, USA) as per the manufacturer's protocol.

2.8. Measurement of catalase enzyme activity {#s0050}
--------------------------------------------

Frozen heart samples were homogenized in ice-cold PBS and centrifuged at 20,000*g* for 10 min at 4 °C. After that, catalase enzyme activity was measured using EnzyChrom^TM^ Catalase Assay Kit (BioAssay Systems, USA) as per the manufacturer's protocol.

2.9. Measurement of cell proliferation {#s0055}
--------------------------------------

Viability of the human A549 lung cancer cells (ATCC, USA) was monitored for 48 h using xCELLigence real-time cell analyzer dual plate (RTCA DP, ACEA Biosciences, USA). In brief, A549 cells were seeded in 100 μL of Dulbecco's modified Eagle's medium (DMEM) in E-16 plate (ACEA Biosciences, USA) at a density of 2 × 10^5^/well. 12 h later (when cells entered the exponential phase), GEF and GEF plus LIRA were added in the final concentration range of 1--30 µM for GEF and 5 µM & 10 µM for LIRA ([@b0090], [@b0120], [@b0210]). Then, cell viability was measured after 12, 24 and 48 h and calculated using RTCA software v. 2.0.

2.10. Statistical analysis {#s0060}
--------------------------

All data are presented as mean ± SD. Statistical analyses were performed on computer using GraphPad Prism software v. 6.01 (CA, USA). Differences between multiple groups were analyzed by one-way analysis of variance (ANOVA) or two-way ANOVA, where required, followed by Tukey's *post hoc* analysis with values of P \< 0.05 were considered significant.

3. Results {#s0065}
==========

3.1. Histopathological examination {#s0070}
----------------------------------

Hematoxylin and eosin (H&E) stained heart sections from the control and LIRA groups showed normal size and shape of the myocardial fibres nuclei and normal thickness of the ventricular myocardium ([Fig. 1](#f0005){ref-type="fig"}A & 1B). Conversely, stained heart sections from the GEF group revealed the presence of mild atypia and hyperchromasia in the myocardial fibres nuclei. Furthermore, heart sections from GEF group exhibited an increase in the thickness of the myocardium, which is most likely due to ventricular hypertrophy ([Fig. 1](#f0005){ref-type="fig"}C). Interestingly, heart sections from LIRA + GEF group showed normal myocardial fibres striations and nuclei similar to the sections from control and LIRA groups ([Fig. 1](#f0005){ref-type="fig"}D). To further investigate the effect of GEF treatment on the cardiac muscle, we measured the body weight (BW), heart weight (HW) and heart weight/body weight ratio (HW/BW), which we used as an indicator of cardiac hypertrophy. As shown in [Table 2](#t0010){ref-type="table"}, we observed a considerable change in the BW in LIRA group compared to the control group. In regard to HW, a significant increase in the HW was observed in GEF treated group compared to other groups ([Table 2](#t0010){ref-type="table"}). Furthermore, a dramatic increase in the ratio of HW/BW was noticed in the GEF-treated group compared to other groups ([Table 2](#t0010){ref-type="table"}). Taken together, results suggest that LIRA treatment protect the heart against GEF-induced hypertrophy as evidenced by histopathological studies.Fig. 1Light micrographs of cardiac tissues using H&E stain. (A) Represents the normal thickness of the ventricular myocardium observed in control group. (B) Cardiac section obtained from LIRA group that shows the presence of normal myocardial fibers (arrow). (C) Represents the increase in the thickness of the myocardium and the presence of mild atypia and hyperchromasia in the myocardial fibers nuclei in GEF-treated rats. These features are induced by myocardial hypertrophy (arrow). (D) Cardiac section obtained from LIRA + GEF group that shows the normal myocardial fibers striations and nuclei (arrow). Objective magnification used was 40x. LIRA, Liraglutide; GEF, Gefitinib.Table 2Body weight, heart weight and heart weight to body weight ratio for rats in each group.ParameterControlLIRAGEFLIRA + GEFBody Weight (g)277.9 ± 12.69260.8 ± 7.35 \*267.9 ± 14.79257.0 ± 7.09 ^\$\$^Heart Weight (mg)921 ± 51.16854 ± 41.07 ^¥^1079 ± 75.95 ^\#^914 ± 66.52 ^Ψ^Heart Weight/Body weight ratio3.42 ± 0.103.50 ± 0.13 ^¥^4.48 ± 0.43 ^\#^3.89 ± 0.20 ^Ψ^[^1]

3.2. Effect of LIRA treatment on cardiac enzymes {#s0075}
------------------------------------------------

To investigate whether GEF treatment is associated with cardiac damage or injury, serum levels of CK-MB, cTn-I/TNNI3 and NT-proBNP were measured in rats after 28 days of treatment. GEF treatment (30 mg/kg) resulted in a significant increase in the serum levels of cardiac enzymes compared to the control group ([Fig. 2](#f0010){ref-type="fig"}). However, the observed increase in the serum levels of CK-MB, cTn-I and NT-proBNP was diminshed in rats pretreated with 200 µg/kg LIRA ([Fig. 2](#f0010){ref-type="fig"}A, B & C, respectively). These results demonstrated that LIRA pretreatment can protect the heart from the damage induced by GEF treartment.Fig. 2Serum levels of cardiac enzymes. Serum from different groups were analyzed to measure CK-MB, cTnI & Pro-BNP levels (A, B & C, respectively). Data are presented as mean ± SD (n = 5). Where \**p* \< 0.05, \*\**p* \< 0.01 & \*\*\**p* \< 0.001. LIRA, Liraglutide; GEF, Gefitinib; CK-MB, Creatine kinase-MB; cTn-I/TnnI3, Troponin I cardiac muscle; NT-proBNP, N-terminal pro-Brain natriuretic peptide.

3.3. Antioxidant properties of LIRA {#s0080}
-----------------------------------

Previous studies reported that LIRA has antioxidant proterties in addition to its established antidiabetic property. Therefore, to determine whether LIRA treatment reduces the cardiac damage induced by GEF, we measured the levels of different pro-oxidant and antioxidant genes, such as NF-κB, PARP and SOD. We found that GEF treatment led to a remarkable rise in the gene and protein expressions of NF-κB compared to the control group ([Fig. 3](#f0015){ref-type="fig"}A & B). Furthermore, a notable decline in the mRNA and protein expressions of the antioxidant gene SOD was observed in the GEF treated rats ([Fig. 3](#f0015){ref-type="fig"}C & D). Strikingly, LIRA pretreatment abolished the increase in the gene and protein expressions of NF-κB that noticed in GEF-treated group ([Fig. 3](#f0015){ref-type="fig"}A & B). Moreover, when combined with GEF, LIRA markedly upregulated the gene and protein expression levels of SOD as shown in [Fig. 3](#f0015){ref-type="fig"}C & D. Furthermore, we measured the protein levels of cleaved PARP, because it was shown that changes in the expression of PARP were associated with oxidative stress and the development of cardiotoxicity. We found that LIRA pretreament significantly mitigated the increase in cleaved PARP levels that induced by GEF ([Fig. 3](#f0015){ref-type="fig"}E).Fig. 3Liraglutide reduces oxidative stress and induces antioxidant genes and proteins. (A) mRNA levels of NF-κB were measured by RT-PCR. (B) Representative western blot analysis of NF-κB protein levels. (C) Densitometric analysis of mRNA expression of SOD. (D) Representative immunoblot analysis of SOD protein levels. (E) Representative blot of cleaved PARP protein levels. Data are presented as mean ± SD (n = 5). Where \**p* \< 0.05 & \*\**p* \< 0.01. LIRA, Liraglutide; GEF, Gefitinib; NF-κB, Nuclear Factor Kappa-B; SOD, Superoxide dismutase; PARP, Poly (ADP-ribose) polymerase; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.

3.4. LIRA activates prosurvival kinases in the heart {#s0085}
----------------------------------------------------

Western blot analysis revealed that GEF treatment resulted in a sharp increase in the protein levels of p-JNK and p-P38 compared to the control group ([Fig. 4](#f0020){ref-type="fig"}A & B). Additionally, the protein levels of p-ERK1/2 and p-Akt were significantly lower in the GEF treated group ([Fig. 4](#f0020){ref-type="fig"}C & D). Nonetheless, rats treated with LIRA significantly attenuated GEF-induced increase in the phosphorylation of JNK and P38 proteins ([Fig. 4](#f0020){ref-type="fig"}A & B). Furthermore, LIRA pretreatment significantly induced the protein levels of the phosphorylated form of ERK1/2 and Akt ([Fig. 4](#f0020){ref-type="fig"}C & D).Fig. 4Liraglutide activates protective signaling pathways in the heart. Representative western blots and relative densitometric analysis of (A) p-JNK, (B) p-P38, (C) p-ERK and (D) p-Akt protein levels. Data are presented as mean ± SD (n = 5). Where \**p* \< 0.05 & \*\**p* \< 0.01. LIRA, Liraglutide; GEF, Gefitinib; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.

3.5. LIRA enhances the activity of antioxidant enzymes {#s0090}
------------------------------------------------------

As shown in [Fig. 5](#f0025){ref-type="fig"}A, the activity of SOD enzyme was markedly reduced in GEF-treated rats as expected. However, LIRA pretreatment restored the enzyme activity to the normal levels ([Fig. 5](#f0025){ref-type="fig"}A). On the other hand, no significant changes between groups were observed in the activity of catalase enzymes ([Fig. 5](#f0025){ref-type="fig"}B).Fig. 5Liraglutide enhances the activity of antioxidant enzymes. Biochemical analysis to measure the activity of the antioxidants SOD (A) and Catalase (B). Data are presented as mean ± SD (n = 5). Where \* *p* \< 0.05 & \*\**p* \< 0.01, while ns means no significant changes were observed (*p* \> 0.05). LIRA, Liraglutide; GEF, Gefitinib; SOD, Superoxide dismutase.

3.6. Effect of LIRA treatment on cell proliferation {#s0095}
---------------------------------------------------

As shown in [Fig. 6](#f0030){ref-type="fig"}, LIRA treatment did not modulate the anti-cancer activity of GEF when combined together. On the contrary, we observed more reduction in the proliferation of A549 cells treated with 5 µM of LIRA plus GEF than in cells treated with GEF alone ([Fig. 6](#f0030){ref-type="fig"}B). However, that reduction was not significant, which means that the cardioprotective effect of LIRA did not attenuate the anti-cancer activity of GEF when combined together.Fig. 6Measurement of cell proliferation. A549 cells were treated with different concentrations of GEF (1 µM -- 30 µM) either alone or with 5 µM and 10 µM LIRA, then the cell proliferation of A549 cells were assessed using RTCA. (A) Densitometric analysis of the average values of cell proliferation after 12 h of treatment. (B) Graphical representation of cell proliferation after 24 h of treatment. Data are presented as mean ± SD (n = 3). LIRA, Liraglutide; GEF, Gefitinib; µM, Micro Molar.

4. Discussion {#s0100}
=============

Our findings in the current study revealed that treatment with GEF for 28 days resulted in cardiac hypertrophy as evidenced by histopathological studies. Furthermore, we observed that GEF treated rats developed cardiac damage, that led to a significant induction of different cardiac enzymes (CK-MB, NT-proBNP and cTnI). At the cellular level, GEF treatment provoked cardiotoxicity through the increase in oxidative stress gene (NF-κB), activation of the stress-activated kinases (p-JNK and p-P38), reduction of antioxidant protein (SOD) and reduction in the prosurvival kinases (p-ERK1/2 and p-Akt). LIRA pretreatment, however, diminished these effects and led to cardioprotection through the activation of the prosurvival kinases and the induction of the antioxidant enzymes.

Tyrosine kinases (TKs) family is a group of proteins which upon stimulation leads to phosphorylation of tyrosine residue in other proteins within the cell. In general, TKs can be divided into RTKs and non-receptor tyrosine kinases (NRTKs) ([@b0055], [@b0125]). GEF is a competitive inhibitor of RTKs activation, especially EGFR activation. It has an extreme affinity to adenosine triphosphate (ATP) binding pocket of the EGFR. Therefore, it competes with ATP to the binding pocket (intracellular tyrosine kinase domain) of the EGFR, consequently inhibits the binding of ATP to the ATP binding pocket ([@b0015], [@b0055], [@b0160]). This inhibition of the binding of ATP results in inhibition of receptor autophosphorylation, which block the downstream signal transduction resulting in inhibition of tumor growth, proliferation and differentiation and eventually induction of apoptosis in cancerous cells ([@b0160]).

It has been reported that GEF treatment induced cardiomyopathy in 56-year-old patient with EGFR-mutated NSCLC. Furthermore, GEF was associated with recurrent myocardial infarction in patient with metastatic carcinoid tumor ([@b0095]). Moreover, it was shown that GEF treatment resulted in cardiotoxicity both *in-vitro* and *in-vivo* ([@b0075]). In that study, researchers reported that treating rats for 21 consecutive days with 30 mg/kg GEF significantly elevated cardiac enzymes and induced the expression of oxidative stress markers, which eventually resulted in cardiac hypertrophy and induction of apoptotic markers. They have reported that the induction of apoptotic markers was associated with GEF-induced hypertrophy. Previous study defined the cardiac hypertrophy as an increase in the size of the cardiac cells that leads to enlargement of the heart ([@b0040]). Furthermore, it has been shown that serum biomarkers, such as natriuretic peptides and cardiac troponin, demonstrate an efficient and novel tool that can reliably estimate the potential and severity of cardiotoxicity induced by anticancer agents ([@b0165]). Our findings in the present study were consistent with previous reports as we showed that GEF treatment resulted in cardiac hypertrophy as validated by histopathology studies. Furthermore, GEF-induced cardiac damage was confirmed by measuring the serum levels of different cardiac enzymes and the levels of pro-oxidant and antioxidant genes in rats treated with GEF for 21 days. At the cellular level, we demonstrated that GEF led to activation of the phosphorylated form of JNK and P38 proteins, which are known to be induced in response to cellular stresses. In contrast, the activation of the pro-survival kinases was attenuated in GEF-treated rats. These findings were in accordance with previous studies as it has been reported that GEF attenuated the activity of ErbB2 and ErbB3 resulting in significant inhibition of the intracellular signaling pathways, such as MAPKs (ERK1/2) and Akt ([@b0025], [@b0160], [@b0195]). Although inhibition of the MAPK and Akt signaling pathways is crucial for treating cancer cells, activation of these pathways is the main mechanism that leads to drug-resistant, which can result in reduced response to the anti-cancer drug, and consequently tumor progression. Based on that, different agents that inhibit the activation of MAPK and PI3K/Akt signaling pathways are now in clinical trials ([@b0060], [@b0110]).

LIRA is glucagon-like peptide-1 (GLP-1) receptor agonist that is used to effectively to treat patients with type 2 diabetes mellitus either as monotherapy or as a combination with other antidiabetic medications. Structurally, it is highly similar (almost 97%) to human GLP-1 amino acid sequence ([@b0030], [@b0045]). Myriad of studies documented the cardioprotective effect of LIRA against different insult ([@b0035], [@b0045], [@b0100], [@b0115], [@b0180], [@b0200]). Recently, it has been shown that the rates of deaths from cardiovascular diseases were remarkably lower in patient with type 2 diabetes mellitus who treated with LIRA ([@b0100]). In that randomized double-blind trial (LEADER trial), LIRA treatment reduced the rates of hospitalization for heart failure, non-fatal stroke, non-fatal myocardial infarction and the death from non-cardiovascular causes in type 2 diabetic patients. The reduction in the rates of deaths from cardiovascular causes among type 2 diabetic patients was shown to be independent of reduction in hypoglycemia ([@b0225]). In animal model, Noyan-Ashraf and his colleagues reported that LIRA offered cardioprotection and improved the cardiac function in diabetic mice subjected to experimental ischemia ([@b0115]). In their study, they pre-treated the mice with LIRA for 7 days, then subject the mice to experimental ischemia. 28 days post MI, they found that LIRA pretreatment notably improved survival, reduced the infarct size, reduced the cardiac rupture and improved cardiac function. These beneficial effects were reported to be independent of reduction in body weight ([@b0115]). It has been suggested that the protective effects of LIRA is mainly due to its antioxidant property as it has been shown that LIRA treatment reduced oxidative stress and restored the anti-oxidant enzymes activity ([@b0005], [@b0030], [@b0135], [@b0220]). Consistent with previous studies, we reported that pretreatment with LIRA protected the heart from GEF-induced cardiac damage and apoptosis as confirmed by histopathology studies. Furthermore, LIRA maintained the serum levels of cTnI, CK-MB and NT-proBNP within normal levels, which are shown to be significantly induced in response to GEF treatment. To further investigate the antioxidant property of LIRA, we measured the expression and the activity of SOD and we demonstrated that LIRA induced SOD gene and protein expression and restored its activity. Furthermore, the induction of pro-oxidant genes that observed in GEF group was mitigated in LIRA pretreated group, suggesting that the protective effect of LIRA is mediated through its antioxidant property.

Many studies reported that activation of ERK1/2 and Akt can efficiently diminish oxidative stress by controlling the expression of different genes. The increase in oxidative stress, however, can in turn generate more reactive oxygen species (ROS), which inhibit the phosphorylation of ERK1/2 and Akt ([@b0185], [@b0205], [@b0215]). In cardiac myocytes, activation of ERK1/2 and Akt and inhibition of the phosphorylation of P38 and JNK were shown to induce protection against myocardial ischemia--reperfusion (IR) injury ([@b0175]). In one study, activation of P38 was shown to alleviate the protective effect induced by insulin against IR injury. Furthermore, it was reported that activation of p-JNK resulted in mitochondrial damage and apoptosis and adult rat cardiomyocytes in response to oxidative stress ([@b0175]). Activation of Akt signaling pathway is fundamental for the protective effect of LIRA ([@b0215]). It has been reported that activation of Akt and ERK signaling pathways reduced apoptosis and oxidative damage through the inhibition of NF-KB ([@b0185]). Furthermore, it has been shown that the protective effect of LIRA in diabetic mice subjected to myocardial IR injury was chiefly mediated through the activation of Akt ([@b0115]). In accordance with previous studies, our results showed that LIRA pretreatment stimulated the phosphorylation of Akt and ERK1/2 proteins and inhibited the activation of stress-activated kinases, P-JNK and p-P38, which in turn protected the heart against the damage induced by GEF.

Although LIRA has been reported to inhibit proliferation and induce apoptosis in MCF-7 and HepG2 cells, little is known regarding the effect of LIRA in A549 cells. In order to investigate whether the use of LIRA in combination with GEF has any effects on the anti-cancer activity of GEF, we measured the proliferation of A549 cells for 48 h. We found that LIRA did not attenuate the anti-cancer activity of GEF when combined together, which indicates the need for further studies to assess the efficacy and safety of such combination.

5. Conclusion {#s0105}
=============

In the present study, we demonstrated that treatment with GEF resulted in cardiac hypertrophy and induction of cardiac enzymes (CK-MB and cTnI). Furthermore, GEF treatment led to increase in oxidative stress genes, reduction of antioxidant proteins and reduction in the prosurvival kinases. LIRA pretreatment, however, diminished these effects and led to cardioprotection through the activation of the prosurvival kinases ([Fig. 7](#f0035){ref-type="fig"}). These findings expand our knowledge about the cardioprotective effect of LIRA, which can help to further investigate the mechanism of protection induced by GLP-1 agonists.Fig. 7Schematic diagram of the cardioprotective effect of LIRA against GEF-induced cardiotoxicity. LIRA, Liraglutide; GEF, Gefitinib; SOD, Superoxide dismutase; CAT, Catalase; NF-κB, Nuclear Factor Kappa-B.
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[^1]: Data are presented as mean ± SD (n = 10). \* Represents comparison between control and LIRA groups; where \**p* \< 0.05. Comparisons between GEF and control are represented by ^\#^; where ^\#^*p* \< 0.05. Comparisons between GEF and LIRA + GEF are represented by ^Ψ^; where ^Ψ^*p* \< 0.05. ^\$^ Represents the comparison between control and LIRA + GEF, where ^\$\$^*p* \< 0.01. Comparsions between LIRA and GEF are represented by ^¥^, where ^¥^*p* \< 0.05. LIRA, Liraglutide; GEF, Gefitinib.
